# A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

> **NCT00946647** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 113 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Panobinostat (LBH589)
- **DRUG:** 5-Azacytidine

## Key facts

- **NCT ID:** NCT00946647
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-02
- **Primary completion:** 2019-04-29
- **Final completion:** 2019-04-29
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2020-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946647, "A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00946647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*